Evidence map›Paper›PMID 39430110›Full record

ReviewFrontiers in toxicology2024

Application and interpretation of immunophenotyping data in safety and risk assessment.

Victor J Johnson, Michael I Luster, Andrew Maier, Corey Boles, Eric W Miller, Daniel E Arrieta

Abstract readReview
In one paragraph

Review in Frontiers in toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Victor J JohnsonBurleson Research Technologies, Inc., Morrisville, NC, United States.
Michael I LusterLuster Assoc. LLC, Morgantown, WV, United States.
Andrew MaierStantec ChemRisk, Cincinnati, OH, United States.
Corey BolesStantec ChemRisk, Raleigh, NC, United States.
Eric W MillerBenchmark Risk Group, Grand Rapids, MI, United States.
Daniel E ArrietaChevron Phillips Chemical Company LP, The Woodlands, TX, United States.

Funding

NICHD NIH HHS HHSN273201400017C
6 · The paper itself

Abstract

The use of immunophenotyping during immunotoxicity investigations was first popularized in the 1980 s and has since become more integrated into diagnostic and non-clinical assessments. The data provided from immunophenotyping can serve as an initial source of information to guide decisions for additional, more advanced, immunotoxicity testing as well as for human health safety and risk assessment of drugs and chemicals. However, comprehensive guidance describing applications of immunophenotyping data in immunotoxicity investigations is lacking, particularly among regulatory bodies. Therefore, a critical examination is needed for the appropriate interpretations and potential misinterpretations of such data during the assessment of drug safety and chemical risk. As such, the current uses and implications of immunophenotyping data in human health safety and risk assessments has been evaluated to provide additional context for the application of current methodologies and guidelines. In addition, case studies are presented to highlight the challenges of interpreting immunophenotyping results along with incorporating the findings into immunotoxicity investigations. Based on the analyses of current approaches and methodologies, a decision flow is presented for use of immunophenotyping data during risk informed decision making.

Indexed as

human health effectsimmunophenotypingimmunotoxicityrisk assessmentsafety

Identifiers

PMID39430110
PMCPMC11486759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.